We made some updates to CKB CORE with a focus on delivering high level, thematic content! To find out more, check out our new quarterly newsletter by clicking here. Have questions or comments? Email us at email@example.com.
Exciting news! CKB CORE and BOOST now include clinical trial locations and contact details! Need more information or have questions? Email us at firstname.lastname@example.org.
CKB UPDATE! CORE and BOOST now include transcripts with version numbers. Questions? Feel free to contact us at email@example.com.
New FDA approval for Atezolizumab plus Cobimetinib and Vemurafenib for patients with BRAF V600-positive advanced melanoma! Find more information on this in CKB CORE. Need up-to-date information on other FDA drug approvals? Consider a CKB BOOST subscription, which includes full access to all drugs and their FDA approvals, along with related content!
CKB BOOST now has AMP/CAP/ASCO evidence level coding!
Vitrakvi (larotrectinib) approved regardless of tumor type for NTRK fusions, except with acquired resistance mutations! Need a list of resistance mutations? Visit ckbhome.jax.org and sign-up for CKB BOOST.